HELP Stock Jumps 6% After TD Cowen Hikes Target Nearly 8x To $62
Helus Pharma (HELP) stock surged 6% after TD Cowen significantly increased its price target from $8 to $62, citing clearer timelines for late-stage data, a new CEO, and positive trends in the psychedelic neuropsychiatry sector. The company's lead drug, HLP003, is in late-stage trials with topline results expected in mid-November 2026. The psychedelic neuropsychiatry sector has seen substantial investment and regulatory progress, contributing to the optimistic outlook.
GKOS Stock Surges 67% Year to Date: What's Driving the Rally?
Glaukos (GKOS) stock has surged 67% year-to-date, significantly outperforming its industry, driven by strong adoption of iDose TR and the successful launch of Epioxa. The company's revenue jumped 49.5% in Q2, leading to an increased 2026 revenue guidance. While the company is expanding its ophthalmology platform and pipeline, investors should consider execution risks related to reimbursement, competition, and new product launches despite the positive growth outlook.
Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO
Seaport Therapeutics (SPTX) recently went public and is being closely watched by major pharmaceutical companies like Bristol Myers Squibb and Johnson & Johnson due to its innovative Glyph prodrug platform. The company, which currently has no product revenue, has 24 drug candidates with its lead asset, GlyphAllo, in Phase 2b trials for MDD, with results expected in the first half of 2027. Its potential for acquisition is high, especially given the history of its CEO, Daphne Zohar, whose previous company Karuna Therapeutics was acquired by Bristol Myers Squibb.
Dividend Giants Pfizer, Chevron, AbbVie: Bold 2027 Price Targets Ahead
This article examines the potential for Pfizer, Chevron, and AbbVie to reach ambitious price targets by 2027, driven by strong quarterly results and strategic initiatives. Pfizer aims for $35 due to its obesity drug pipeline and cost savings, while Chevron targets $250 supported by its Guyana assets, Hess synergies, and a power deal with Microsoft. AbbVie eyes $325, propelled by the growth of Skyrizi and Rinvoq, along with an acquisition.
Vest Financial LLC Sells 3,946 Shares of AbbVie Inc. $ABBV
Vest Financial LLC reduced its stake in AbbVie Inc. by 1.4% in the second quarter, selling 3,946 shares and retaining 268,319 shares valued at approximately $67.5 million. Other institutional investors have also adjusted their positions, and institutional ownership collectively stands at 70.23% of ABBV. Additionally, AbbVie reported strong quarterly earnings, exceeding expectations with $3.65 EPS and $16.99 billion in revenue, while maintaining a $1.73 quarterly dividend.
Benjamin Edwards Inc. Reduces Position in AbbVie Inc. $ABBV
Benjamin Edwards Inc. decreased its stake in AbbVie Inc. by 3.4% during the second quarter, now holding 327,322 shares valued at $82.385 million. Despite this reduction, other institutional investors like Norges Bank and Wellington Management Group LLP significantly increased their holdings in AbbVie. The article also covers AbbVie's recent financial performance, dividend announcement, key news, and updated analyst price targets.
GUBRA: Revenue fell after last year's AbbVie deal, but clinical and CRO progress support long-term growth
GUBRA's revenue and earnings decreased year-over-year due to the absence of a large one-time deal with AbbVie. However, the company showed operational progress with key obesity assets moving into clinical stages and its Contract Research Organization (CRO) revenue increasing by 11% sequentially. GUBRA reaffirmed its 2026 guidance and expanded its innovation and infrastructure platforms, indicating support for long-term growth.
GUBRA: Revenue fell sharply after last year's AbbVie deal, but pipeline and CRO growth continued
GUBRA experienced a sharp decline in revenue and profit year-over-year due to the absence of a significant one-time deal with AbbVie. Despite this, the company maintained operational momentum through new clinical trials, growth in its Contract Research Organization (CRO) services, and the launch of Gubra Ventures, while continuing to invest in R&D and infrastructure.
Genmab Speeds Toward New Product Launches In 2027
Genmab is preparing for two new product launches in 2027, building on the commercial groundwork laid by Epkinly and Tivdak. The company's stock price has seen a significant increase following its first-half 2026 update. These upcoming launches stem from recent deals, indicating a strategic expansion of their product pipeline.
BioMarin to acquire Alesta Therapeutics for up to $490 million
BioMarin Pharmaceutical Inc. has announced a definitive agreement to acquire Alesta Therapeutics for up to $490 million. The acquisition involves an upfront cash payment of $275 million for Alesta's lead asset, ALE1, a therapy for hypophosphatasia, with potential additional milestone payments of up to $215 million. Existing Alesta shareholders will retain interests in a newly formed entity for non-ALE1 assets, and the transaction is expected to close in Q3 2026.
AbbVie Raises $9 Billion Debt to Fund Acquisition
AbbVie recently completed a $9 billion debt offering consisting of unsecured senior notes maturing between 2028 and 2066. The primary purpose of this debt issuance is to finance its acquisition of Apogee Therapeutics, with a provision for redemption if the deal falls through. Analysts currently rate ABBV stock as a Buy with a $300 price target, though TipRanks' AI Analyst, Spark, identifies it as Neutral due to strong cash generation offset by high debt.
Bristol Myers Squibb to build $2.3B manufacturing campus in Houston
Bristol Myers Squibb announced a $2.3 billion investment to construct a 600,000-square-foot high-tech medicine manufacturing campus in Houston. This project, part of a larger domestic growth strategy, is expected to create about 500 jobs and will produce small molecules, biologics, and antibody-drug conjugates. The modular design will allow for flexibility and future integration of digital and automation advancements, making Houston a key hub in the company's manufacturing network.
Is AbbVie Stock About To Break Out Again?
AbbVie (ABBV) stock is trading at the top of its 52-week range, driven by the potential for a new subcutaneous induction option for its immunology drug SKYRIZI in Crohn's disease, which is currently under regulatory review. This dosing change is expected to accelerate SKYRIZI sales, a drug that already accounts for nearly a third of AbbVie's guided revenue and has seen its sales forecast raised twice this year. The company anticipates the commercial impact of this change to materialize in early 2027, potentially leading to further stock re-rating.
Sarepta Therapeutics Delivers Q2 Operating Profit as CEO Transition Advances Pipeline
Sarepta Therapeutics reported strong Q2 2026 financial results, including $328.7 million in net product revenue and both GAAP and non-GAAP operating income, driven by PMO and ELEVIDYS sales. The company also announced the appointment of Michael Severino as its new CEO, who will lead Sarepta's continued advancement of its rare disease pipeline, with key data readouts for DM1 and FSHD expected in H2 2026 and a new Huntington's disease program initiated. Despite a year-over-year revenue decrease attributed to an updated ELEVIDYS label and a missed milestone payment, Sarepta narrowed its 2026 revenue guidance to $1.2 billion to $1.3 billion and ended Q2 with a robust cash position of approximately $945 million.
Munich Reinsurance Co Stock Corp in Munich Has $39.59 Million Holdings in AbbVie Inc. $ABBV
Munich Reinsurance Co Stock Corp in Munich increased its holdings in AbbVie Inc. by 3.8% in the second quarter, bringing its total to 157,348 shares valued at approximately $39.6 million. Institutional investors collectively own 70.23% of AbbVie. The company reported strong quarterly earnings and revenue, exceeding analyst expectations, and has a "Moderate Buy" consensus rating with an average price target of $275.73.
Welch Group LLC Increases Holdings in AbbVie Inc. $ABBV
Welch Group LLC increased its stake in AbbVie Inc. (NYSE:ABBV) by 1.5% in the second quarter of 2026, bringing its total holdings to 371,366 shares valued at $93.45 million. Institutional investors collectively own 70.23% of AbbVie, which maintains a "Moderate Buy" rating from analysts with an average price target of $275.73. The company recently exceeded Q2 earnings expectations with $3.65 EPS and $16.99 billion in revenue, also declaring a quarterly dividend of $1.73 per share.
Insider Selling: AbbVie (NYSE:ABBV) EVP Sells 32,710 Shares
AbbVie (NYSE:ABBV) Executive Vice President Nicholas Donoghoe sold 32,710 shares of the company's stock for approximately $8.18 million, reducing his stake by 30.53%. This sale occurred after AbbVie reported strong quarterly earnings, beating revenue and EPS estimates, and provided positive Q3 2026 guidance. The stock currently holds a "Moderate Buy" consensus rating with an average analyst price target of $275.73 and offers a quarterly dividend of $1.73 per share.
Smith & Nephew drops 3.5% as finance chief quits
Smith & Nephew PLC shares fell by 3.5% after its finance chief, John Rogers, announced his immediate departure from the board to take a new position in the US, with his official exit as CFO scheduled for September 30. Rogers' departure follows three years at the company, during which he contributed to improving financial performance and developing the RISE strategy. Pierre Palassian will serve as interim chief financial officer while the company searches for a permanent replacement.
Smith & Nephew CFO John Rogers To Step Down In September
Smith & Nephew announced that CFO John Rogers will step down from his position on September 30, 2026, to pursue an external opportunity in the US. Pierre Palassian, Senior Vice President Finance and Group Controller, will serve as interim CFO while the company searches for a permanent successor. CEO Deepak Nath thanked Rogers for his contributions to the company's financial performance and strategic development.
REG - Smith & Nephew Plc - Directorate change
Smith+Nephew announced that its Chief Financial Officer, John Rogers, will resign on September 30, 2026, to take an external position in the US. Pierre Palassian, Senior Vice President Finance and Group Controller, will serve as interim CFO while the company searches for a successor. Rogers will not receive a severance payment, and his outstanding incentive awards will be treated in accordance with rules for ordinary leavers.
First Tracks Biotherapeutics CBO Benjamin Stone Receives 60,492 Performance Stock Units
Benjamin Stone, Chief Business Officer of First Tracks Biotherapeutics, Inc. (NASDAQ: TRAX), was granted 60,492 performance stock units (PSUs) on August 15, 2026. This grant followed the certification of performance goals by the Compensation Committee. The PSUs will vest in two equal installments on August 15, 2027, and July 1, 2028, contingent on Stone's continued service, increasing his total beneficial PSU holdings to 137,651.
Smurfit Westrock CFO Ken Bowles Acquires 234 Dividend-Equivalent RSUs
Ken Bowles, Executive Vice President and Group CFO of Smurfit Westrock plc (NYSE:SW), acquired 234 ordinary shares through dividend-equivalent restricted stock units (RSUs) on August 14, 2026. These RSUs were credited based on the company's quarterly dividend of $0.4523 per ordinary share and were acquired at no cash cost. Following this transaction, Bowles beneficially owns 174,347 ordinary shares, including 38,840 RSU awards that vest in three equal annual installments.
Halozyme Appoints Dannielle Appelhans to its Board of Directors
Halozyme Therapeutics, Inc. announced the election of Dannielle Appelhans to its Board of Directors. Ms. Appelhans brings over 20 years of executive leadership in the biotechnology and pharmaceutical industries, with significant expertise in operations, manufacturing, and supply chain management. Her experience will be a key asset as Halozyme continues to advance its drug delivery technology platforms and growth strategy.
Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C
Johnson & Johnson is poised to lead Delix Therapeutics' $85M Series C funding round, valuing the neuroplastogen developer at $190M pre-money. Delix, known for its non-hallucinogenic psychedelic approach, recently announced positive Phase Ib results for its lead candidate, zalsupindole (DLX-001), for major depressive disorder. This investment marks a significant entry for a major pharmaceutical company into the non-hallucinogenic psychedelic space, despite recent challenges faced by Delix.
Timberland Bancorp EVP Breanne D. Antich Sells 30 Shares of Common Stock on August 18, 2026
Breanne D. Antich, EVP and CTO of Timberland Bancorp Inc (NASDAQ: TSBK), sold 30 shares of the company's common stock on August 18, 2026, at a price of $46.4142 per share. Following this transaction, Antich directly owns 3,890 shares and indirectly holds an additional 4,174 shares through the company's employee stock ownership plan. The shares sold were part of a Restricted Stock Award granted in September 2024, vesting over five years.
AbbVie completes $8.0 billion notes offering to support Apogee Therapeutics acquisition
AbbVie Inc. has completed an $8.0 billion senior notes offering to partially fund its acquisition of Apogee Therapeutics, Inc. The offering includes various series of notes with different interest rates and maturity dates, increasing AbbVie's total debt to approximately $78.9 billion. The company also reported strong second-quarter 2026 revenues and raised earnings per share, leading to increased price targets from several analysts.
AbbVie completes $8.0 billion notes offering to support Apogee Therapeutics acquisition
AbbVie Inc. has successfully completed an $8.0 billion senior notes offering to finance its acquisition of Apogee Therapeutics, Inc. The offering comprises several series of notes with varying maturities and interest rates, bringing AbbVie's total debt to approximately $78.9 billion. An InvestingPro tip highlights that AbbVie's short-term obligations currently exceed its liquid assets.
AbbVie completes $8.0 billion notes offering to support Apogee Therapeutics acquisition
AbbVie Inc. has successfully completed an $8.0 billion senior notes offering to finance its acquisition of Apogee Therapeutics, Inc. The offering includes various series of notes with different maturity dates and interest rates, which will increase AbbVie's total debt to approximately $78.9 billion. An InvestingPro tip indicates that AbbVie's short-term obligations currently exceed its liquid assets.
AbbVie completes $8.75B note offering to fund Apogee acquisition
AbbVie completed an $8.75 billion underwritten notes offering to finance a portion of its acquisition of Apogee Therapeutics. The offering included floating-rate notes due in 2028 and fixed-rate notes with maturities ranging from 2028 to 2066, with fixed coupons from 4.500% to 6.100%. The net proceeds will primarily cover the cash consideration for the Apogee acquisition and related fees, with any remaining funds allocated for general corporate purposes.
AbbVie (NYSE: ABBV) issues new senior notes with Apogee-linked redemption
AbbVie (NYSE: ABBV) has completed a public offering of multiple series of unsecured, unsubordinated senior notes to finance its acquisition of Apogee Therapeutics, Inc. The offering includes a mix of floating-rate and fixed-rate notes with maturities ranging from 2028 to 2066. A special mandatory redemption clause requires AbbVie to redeem notes maturing between 2028 and 2038 at 101% of principal plus accrued interest if the Apogee acquisition is not completed.
AbbVie Inc Stock (ABBV) Closed Up by 3.48% on Aug 18: Key Drivers Unveiled
AbbVie Inc (ABBV) saw its stock close up by 3.48% on August 18, driven by positive investor sentiment following the successful completion of a multi-billion dollar debt offering to fund the Apogee acquisition and strong second-quarter revenue growth. The company's performance was further bolstered by robust adoption rates for key immunology treatments and positive analyst ratings, despite facing challenges such as earnings dilution from the acquisition and competition for legacy products.
Revance hires Janelle Wichmann as chief marketing officer of skincare unit
Revance has appointed Janelle Wichmann, formerly of Ulta Beauty and Procter & Gamble, as its new Chief Marketing Officer for its skincare unit. Her primary role will be to boost the commercial penetration of Daxxify, Revance's rival to Botox. Wichmann will oversee marketing strategy, brand development, and commercial growth initiatives, aiming to strengthen innovation and deepen engagement with consumers and healthcare professionals.
A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
A new category is emerging in medical aesthetics focused on bioregenerative tissue restoration rather than just volume replacement. Companies like Conexeu Sciences Inc. are developing technologies based on the extracellular matrix to prompt the body to rebuild tissue. This shift is driven by advancements in science, patient demand for natural-looking results, and the increasing need for soft-tissue restoration following significant weight loss from GLP-1 medications.
AbbVie Inc. stock outperforms competitors on strong trading day
AbbVie Inc. (ABBV) stock rallied 3.43% to $258.92 on Tuesday, outperforming the broader market despite a grim trading session where the S&P 500 Index and Dow Jones Industrial Average both fell. This marks the second consecutive day of gains for AbbVie. The article highlights AbbVie's strong performance relative to its competitors and the overall market trend.
AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support
AbbVie announced the recipients of its 2026 AbbVie Immunology Scholarship, marking the program's 10th anniversary. This year, 34 students living with inflammatory conditions will receive the scholarship, which has invested over $6 million to support more than 350 students in higher education since 2016. The scholarship now offers renewable awards of up to $20,000 per student to help address the financial and health-related challenges faced by students with chronic illnesses.
Abbott Laboratories $ABT Shares Purchased by Mission Wealth Management LP
Mission Wealth Management LP significantly increased its stake in Abbott Laboratories (NYSE:ABT) by 100.5% in the second quarter, now holding 48,849 shares valued at $4.43 million. Other institutional investors also adjusted their positions, with overall institutional ownership at 75.18%. Analysts have a "Moderate Buy" consensus rating for Abbott, with an average price target of $118.67, despite some recent price target reductions.
Barclays Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)
Barclays has reaffirmed its "Buy" rating on Eli Lilly & Co (LLY) with a price target of $1,400.00. Analyst Emily Field, who covers the Healthcare sector, has a 1.9% average return and 45.77% success rate on recommended stocks. Eli Lilly & Co reported strong financial results for the quarter ending June 30, with revenues of $22.97 billion and a net profit of $7.1 billion.
Capital Advisors Inc. OK Raises Stock Position in AbbVie Inc. $ABBV
Capital Advisors Inc. OK increased its stake in AbbVie Inc. (NYSE:ABBV) by 11.2% in the second quarter, now owning 447,129 shares valued at $112.5 million. Institutional investors collectively hold 70.23% of AbbVie's stock, and analysts maintain a "Moderate Buy" rating with an average target price of $275.73. The company recently reported strong quarterly earnings, beating expectations, and declared a quarterly dividend of $1.73 per share, yielding 2.8%.
Abundance Wealth Counselors Boosts Holdings in AbbVie Inc. $ABBV
Abundance Wealth Counselors significantly increased its stake in AbbVie Inc. (NYSE:ABBV) by 95.4% during the second quarter, now owning 30,368 shares valued at $7.64 million. Other institutional investors like Vanguard Group Inc., State Street Corp, Geode Capital Management LLC, and Bank of America Corp DE also modified their holdings. AbbVie reported strong Q2 earnings with $3.65 EPS and $16.99 billion in revenue, with analysts maintaining a "Moderate Buy" consensus rating.
AbbVie Inc. $ABBV Shares Acquired by ABN Amro Investment Solutions
ABN Amro Investment Solutions significantly increased its holdings in AbbVie Inc. (NYSE:ABBV) during the second quarter, now owning 649,098 shares worth $163.3 million. Several other institutional investors also adjusted their positions in the company. Analysts maintain a "Moderate Buy" consensus rating for AbbVie, with a target price of $275.73, and the company recently declared a quarterly dividend of $1.73 per share.
Sarepta Posts US$328.7M Results
Sarepta Therapeutics Inc. (SRPT:NASDAQ) reported Q2 2026 product revenue of US$328.7 million, driven by PMO and ELEVIDYS sales, and announced Michael Severino as its new CEO. The company narrowed its 2026 revenue guidance to US$1.2 billion to US$1.3 billion and expects important data readouts for its DM1 and FSHD programs in the second half of 2026. Despite a decrease in total revenue compared to Q2 2025 due to updated ELEVIDYS labeling and the absence of a milestone payment, Sarepta maintains a strong balance sheet and an active pipeline for rare diseases.
AbbVie Inc. (ABBV) Stock Analysis: Navigating Growth With A 10.74% Potential Upside
AbbVie Inc. (ABBV) holds a formidable position in the pharmaceutical industry with a market capitalization of $440.83 billion and a diverse portfolio including treatments for autoimmune diseases, blood cancers, and neurological disorders. Analysts project a potential upside of 10.74%, with an average target price of $276.24, supported by 25 buy ratings. While the company demonstrates strong financial health with $16.87 billion in free cash flow and a 10.20% revenue growth, investors should consider the high dividend payout ratio of 190.40% against its long-term profitability.
Apogee Therapeutics CMO Dambkowski sells $737k in stock
Carl Dambkowski, CMO of Apogee Therapeutics, sold 5,500 shares for $737,934 on August 5, 2026, under a pre-arranged trading plan, while also exercising options to acquire 4,125 shares. This transaction occurred near the stock's 52-week high and after the company's acquisition by AbbVie was approved by shareholders for $10.9 billion. Analysts subsequently downgraded Apogee's stock, though some increased price targets to reflect the acquisition value.
J&J Secures $2.58B Option to Acquire Sail Biomedicines
Johnson & Johnson has secured an exclusive option to acquire Sail Biomedicines for $2.58 billion, backing Sail's in vivo CAR T platform for immune-mediated diseases. This collaboration marks J&J's largest investment in in vivo cell therapy to date, aiming to develop more scalable CAR T treatments that reprogram immune cells directly inside the patient, circumventing the complex ex vivo manufacturing process. Initial payments from J&J total $785 million, with potential for more upon achieving development milestones, as Sail's lead asset, SAIL-0839, remains in preclinical development.
Weekly Recap: $1.3B cash, $85.9M loss and directors resign on AbbVie deal
Apogee Therapeutics, Inc. (NASDAQ: APGE) reported $1.3 billion in cash but an $85.9 million net loss in Q2 2026, primarily due to increased spending on its zumilokibart program. Its directors are set to resign following the closing of the AbbVie acquisition, which will make Apogee an indirect wholly owned subsidiary of AbbVie.
Wells Fargo raises Abbvie stock price target on HS drug potential
Wells Fargo has increased its price target for AbbVie (NYSE:ABBV) to $300 from $295, maintaining an Overweight rating, due to the strong potential of its Hidradenitis suppurativa (HS) drugs. The firm anticipates $6.5 billion in peak sales for AbbVie in the HS market, believing the market underestimates both the opportunity and AbbVie's multi-product leadership potential. This optimism is supported by upcoming second-half 2026 catalysts and positive analyst sentiment, despite the stock trading near its 52-week high and appearing overvalued according to some analyses.
Bellecapital International Ltd. Acquires 8,728 Shares of AbbVie Inc. $ABBV
Bellecapital International Ltd. increased its stake in AbbVie Inc. by 13% during the second quarter, acquiring an additional 8,728 shares, bringing its total holdings to 75,615 shares valued at approximately $19.0 million. Institutional investors and hedge funds now collectively own 70.23% of AbbVie. The company continues to receive positive analyst sentiment and has a "Moderate Buy" rating with an average target price of $275.50, driven by strong earnings, neuroscience growth, and post-Humira diversification strategies.
AbbVie Inc. $ABBV Shares Bought by Confluence Wealth Services Inc.
Confluence Wealth Services Inc. increased its stake in AbbVie Inc. (NYSE:ABBV) by 38.6% in the second quarter, bringing its total holdings to 38,846 shares valued at $9.775 million. Institutional investors collectively own 70.23% of AbbVie shares. The company has a "Moderate Buy" consensus rating from analysts, with an average price target of $275.50, and recently exceeded earnings and revenue expectations.
AbbVie Inc. $ABBV Shares Bought by Exchange Traded Concepts LLC
Exchange Traded Concepts LLC significantly increased its stake in AbbVie Inc. by 204.3% in Q2, bringing its total holdings to 105,544 shares valued at $26.6 million. This comes as AbbVie reported strong Q1 2026 earnings, with revenue up 12.4% year-over-year and EPS exceeding expectations, driven by growth in its neuroscience, immunology, and aesthetics portfolios. Analysts maintain a "Moderate Buy" rating for ABBV with an average price target of $275.50, despite some concerns about valuation and pipeline uncertainty.
Should Income Investors Look At Amgen Inc. (NASDAQ:AMGN) Before Its Ex-Dividend?
Amgen Inc. (NASDAQ:AMGN) is approaching its ex-dividend date, with a trailing yield of 2.4% and an upcoming dividend of US$2.52 per share. The company's dividend payouts are covered by both profit (60% payout ratio) and free cash flow (52% consumed), suggesting sustainability. While earnings per share have grown modestly at 5.5% over the last five years and dividends have increased by 9.7% annually over the past decade, the article suggests investors might want to research growth reinvestment opportunities due to current dividend prospects.
